Skip to content

Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal metastasis from colorectal or appendiceal cancer: a feasibility study

Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal metastasis from colorectal or appendiceal cancer: a feasibility study - Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal metastasis from colorectal or appendiceal cancer: a feasibility study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000021325
Enrollment
10
Registered
2016-03-03
Start date
2015-03-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peritoneal metastasis from colorectal or appendiceal cancer

Interventions

Sponsors

National Center for Global Health and Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Histologically proven colon or appendiceal cancer; peritoneal metastasis; age between 20 and 80 years; Synchronous or metachronous metastasis; Eastern Cooperative Oncology Group performance status 0-1; adequate bone marrow function ; and borderline resectable distant metastasis

Exclusion criteria

Exclusion criteria: 1) Patient who has a history of multiple cancers within 5 years before registration, with the exception of carcinoma in situ and a disease equivalent to intramucosal carcinoma. 2) Patient who is associated with unstable angina pectoris that occurred or worsened within 3 weeks before registration, or patient with a history of cardiac infarction that developed within 6 months before registration. 3) Patient with serious diseases including uncontrolled congestive cardiac failure and abnormal cardiac rhythm. 4) Patient who is associated with or has a history of either fibroid lung or interstitial pneumonia or both. Patient with imaging findings suggestive of the diseases. 5) Patient who is pregnant or breast feeding, or who refuses to use appropriate birth control. 6) Patient whose consent is suspicious in terms of his/her mental and legal state. 7) Patient who is considered by the investigator to be unsuitable for enrollment.

Design outcomes

Primary

MeasureTime frame
safety

Secondary

MeasureTime frame
1-year overall survival rate

Countries

Japan

Contacts

Public ContactYoshimasa Gohda

National Center for Global Health and Medicine Department of Surgery

ygohda@hosp.ncgm.go.jp03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026